Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population.

OBJECTIVE: The KRAS gene has a pathophysiological role in the development of many cancers. This study aims to investigate the relationship between KRAS polymorphisms and genetic susceptibility to breast cancer. METHOD: The rs712, rs12587 and rs9266 gene loci in the KRAS gene of 421 subjects (141 breast cancer patients, 141 benign breast tumours and 139 healthy controls) were analysed by the polymerase chain reaction and SNaPshot sequencing. Transcriptomic information on KRAS and corresponding clinical information was downloaded from the TCGA and GTEx databases. Differences in KRAS expression between breast cancer tissues and control tissues were analysed. RESULTS: We found no significant association between KRAS rs712 and rs12587 locus gene polymorphisms and an increased risk of developing benign breast tumours and breast cancer (p > 0.05). The KRAS rs9266 locus mutation heterozygous model CT and dominant model CT + TT were significantly associated with an increased risk of breast cancer (both p < 0.05). In addition, the TAT haplotype was expressed at an increased frequency, and the GAC haplotype was expressed at a reduced frequency in breast cancer compared with controls (both p < 0.05). We found that KRAS was over expressed in breast cancer tumour tissues compared with the control tissues (p < 0.0001). CONCLUSION: The KRAS rs9266 gene polymorphism and the TAT haplotype may be associated with an increased risk of breast cancer in Chinese women. The GAC haplotype may be a protective factor against breast cancer.

The Clinical Application Value of RDW, CA153, and MPV in Breast Cancer.

BACKGROUND: Early detection of tumors is beneficial to the treatment of patients. Certain indicators in the blood routine, such as red blood cell distribution width (RDW), are considered to be used to assess the patient's condition and prognosis. Mean platelet volume (MPV) is also used to assess the prognosis of patients. Carbohydrate antigen 153 (CA153) is considered to be a more specific antigen marker for breast cancer. The purpose of our study was to explore the diagnostic value of RDW, MPV, and CA153 for breast cancer (BC) and breast hyperplasia (BH). METHODS: The study included 104 breast cancer patients, 100 breast hyperplasia patients, and 100 healthy controls. CA153 was detected by an automatic electrochemical luminescence analyzer (Cobas e601, Roche Diagnostics, Switzerland). The concentration of RDW and MPV in serum was measured by Sysmex XN-10-B3 (Sysmex, Ja¬pan). RESULTS: Compared with the breast hyperplasia group, the RDW and CA153 of the breast cancer group were increased. The healthy control group, mammary gland hyperplasia group, and breast cancer were positively correlated with RDW and CA153. Logistic regression results show that increasing age, increasing RDW, and increasing CA153 can increase the risk of breast cancer. The area under the ROC (AUC) analysis showed that the combined specificity and sensitivity of the combined application of RDW, MPV, and CA153 for the identification of breast cancer is better than that of a single marker. CONCLUSIONS: The combined application of RDW, MPV, and CA153 can improve the differential diagnosis of breast cancer and breast hyperplasia.

The relationship between polymorphism of IGF2BP2 gene rs4402960 and risk of pan-cancer: a meta-analysis and a bioinformatics analysis.

OBJECTIVE: To conduct a meta-analysis and a bioinformatics analysis to assess the relationship between IGF2BP2 gene polymorphism and pan-cancer risk. METHODS: PubMed, EMBASE, and Web of Science were conducted to literature searches. The heterogeneity test was used in five genetic models. Odds ratios (OR), 95% confidence intervals (CI), and p-values were used to evaluate the combined effects of various genetic models. Subgroup analysis and Meta-regression analysis were used to analyze the characteristics of heterogeneity. Sensitivity analysis and publication bias were also performed. Transcriptomic information on IGF2BP2 was downloaded and analyzed from the TCGA and GTEx databases. GEPIA (http://gepia.cancer-pku.cn/) was performed to analyze the relationship between IGF2BP2 expression and cancer tissue. RESULTS: This meta-analysis contained 7 case-control studies, with 5,908 cases and 7,890 controls. There were significant differences in the heterozygous genetic model of IGF2BP2 gene rs4402960 polymorphism (OR = 1.080, 95% CI = 1.003-1.163, p = 0.041). In subgroup analysis based on ethnicity, There was a statistical significant association in Chinese (heterozygous: OR = 1.110, 95% CI = 1.010-1.220, p = 0.030). Bioinformatics analysis found that IGF2BP2 was over-expressed in pan-cancer (p < 0.01). In addition, the Kaplan-Meier estimate showed that there is statistical significance of OS between the low and high IGF2BP2 TPM groups in Lung adenocarcinoma (p <0.001). CONCLUSIONS: To sum up, IGF2BP2 gene polymorphism may be related to cancer risk. IGF2BP2 has diagnostic value in the diagnosis and treatment of pan-cancer.